ROSCREA, Ireland, Dec. 23, 2021 /PRNewswire/ – Renexxion Ireland
Ltd., a private biopharmaceutical company committed to delivering
innovative drugs to patients with high unmet need gastrointestinal
("GI") disorders, announced today the issuance of a new US patent
covering composition-of-matter of its lead drug candidate,
naronapride, a unique late-stage GI prokinetic. The patent is also
being prosecuted worldwide. Renexxion Ireland holds the worldwide
rights to develop and commercialize naronapride.
- The new US composition-of-matter patent extends the loss of
exclusivity for naronapride to 2038, excluding any patent-term
adjustment.
- Naronapride is currently being developed for commercialization
initially for high unmet medical need in gastroparesis in
Greater Europe (including UK),
Russia, Central Asian Republics
and certain Australasian countries by its European licensing
partner.
- Renexxion Ireland is considering potential development and
commercialization partners in other areas worldwide, such as
Greater China, Japan, and, possibly, North America.
Naronapride is a late-phase clinical stage drug candidate which
possesses a unique combination of both serotonin 5HT4-receptor
agonistic and dopamine D2-receptor antagonistic properties, both of
which are clinically validated targets and work in both the upper
and lower GI tract. Currently, the options to treat dysmotility
disorders of the GI tract such as gastroparesis and other disorders
such as IBS-c, GERD, and CIC, are limited.
"The new patent enables the company to develop and commercialize
naronapride for multiple gastrointestinal disorders requiring a
prokinetic over the next two decades in order to establish it as a
potential best-in-class prokinetic." said Peter Milner M.D., FACC, Chairman and CEO.
About unmet GI motility disorders
No safe and effective GI motility agent is currently available
to patients. The last such agents approved were cisapride
(Propulsid®) and tegaserod (Zelnorm®), which each sold over
$1Bn annually and were withdrawn over
10 years ago due to cardiac safety concerns.
About Naronapride – Potential best-in-class blockbuster for
unmet GI indications
Naronapride is a late-phase clinical stage drug candidate which
possesses a unique combination of both 5HT4 agonistic and D2
antagonistic properties and works in both upper and lower GI. It is
locally active in gut lumen, designed to be minimally absorbable,
side-effect profile indistinguishable from placebo. Four positive
Phase 2 studies completed in upper and lower GI indications and is
Phase 3 ready in CIC (chronic idiopathic constipation) and GERD
(gastro-esophageal reflux). Naronapride was engineered to avoid any
cardiac safety risk. Its oral formulation serves large unmet needs
in CIC, IBS-c, PPI-resistant GERD and gastroparesis.
About Renexxion:
Renexxion Ireland Ltd. is a privately held biopharmaceutical
company committed to delivering new drugs to patients with GI
motility disorders with its operations and drug development team
based in Ireland. For more
information, refer to http://www.rnexltd.ie.
Contact: Catherine
Pearson, Chief Operating Officer, at Press@rnexltd.ie, or on
+353 61 539121
View original
content:https://www.prnewswire.com/news-releases/renexxion-ireland-announces-issuance-of-a-new-us-patent-covering-naronapride-a-clinical-stage-potential-best-in-class-prokinetic-agent-for-gastrointestinal-disorders-301450410.html
SOURCE Renexxion Ireland Ltd.